[1] Cheng D, Roder E. Pyrrolizidine Alkaloids from Emilia sonchifolia. Planta Med, 1986, 6:484-486.
[2] Gilcy GK, Kuttan G. Immune response modulatory effect of Emilia sonchifolia (L.) DC: an in vivo experimental study. J Basic Clin Physiol Pharmacol, 2015, 26:613-622.
[3] Shylesh BS, Padikkala J. In vitro cytotoxic and antitumor property of Emilia sonchifolia (L.) DC in mice. J Ethnopharmacol, 2000, 73:495-500.
[4] Gilcy GK, Kuttan G. Evaluation of antiangiogenic efficacy of emilia sonchifolia (L.) DC on tumor-specific neovessel formation by regulating MMPs, VEGF, and proinflammatory cytokines. Integr Cancer Ther, 2016, 15:NP1-NP12.
[5] George GK, Kuttan G. Inhibition of pulmonary metastasis by Emilia sonchifolia (L.) DC: An in vivo experimental study. Phytomedicine, 2016, 23:123-130.
[6] Nworu CS, Akah PA, Okoye FB, et al. Inhibition of pro-inflammatory cytokines and inducible nitric oxide by extract of Emilia sonchifolia L. aerial parts. Immunopharmacol Immunotoxicol, 2012, 34:925-931.
[7] Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood, 1995, 85:3005-3020.
[8] Valla DC, Cazals-Hatem D. Sinusoidal obstruction syndrome. Clin Res Hepatol Gastroenterol, 2016, 40:378-385.
[9] DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis, 2002, 22:27-42.
[10] Edgar JA, Molyneux RJ, Colegate SM. Pyrrolizidine alkaloids: potential role in the etiology of cancers, pulmonary hypertension, congenital anomalies, and liver disease. Chem Res Toxicol, 2015, 28:4-20.
[11] Liu F, Rong X, Guo H, et al. Clinical characteristics, CT signs, and pathological findings of Pyrrolizidine alkaloids-induced sinusoidal obstructive syndrome: a retrospective study. BMC Gastroenterol, 2020, 20:30.
[12] Yang XQ, Ye J, Li X, et al. Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes. World J Gastroenterol, 2019, 25:3753-3763.
[13] Ou P, Liu X, Tang Z, et al. Gynura Segetum Related Hepatic Sinusoidal Obstruction Syndrome: a liver disease with high mortality and misdiagnosis rate. Curr Pharm Des, 2019, 25:3762-3768.
[14] 中华医学会消化病学分会肝胆疾病协作组.吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见(2017年,南京).中华消化杂志,2017,37:513-522.
[15] Bayraktar UD, Seren S, Bayraktar Y. Hepatic venous outflow obstruction: three similar syndromes. World J Gastroenterol, 2007, 13:1912-1927.
[16] 李瑭,王一娜,尹琼丽,等.中药一点红致肝小静脉闭塞病1例并文献复习.世界华人消化杂志,2016,24:158-164.
[17] Wang Y, Qiao D, Li Y, et al. Risk factors for hepatic veno-occlusive disease caused by Gynura segetum: a retrospective study. BMC Gastroenterol, 2018, 18:156.
[18] 徐楠,李江,谢琴秀.43例吡咯生物碱相关肝窦阻塞综合征临床特征及预后分析.安徽医学,2020,41:797-800.
[19] Peng C, Zhang X, Zhang F, et al. Clinical efficacy and safety of anticoagulation therapy for Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: a retrospective multicenter cohort study. Eur J Gastroenterol Hepatol, 2020, 32:1168-1178.
[20] Akyuz C, CaClar K, Emir S, et al. High-dose methylprednisolone treatment of hepatic veno-occlusive disease in a child with Wilms tumor. Pediatr Hematol Oncol, 2003, 20:345-349.
[21] Senzolo M, Cholongitas E, Patch D,et al. TIPS for veno-occlusive disease: is the contraindication real?.Hepatology, 2005, 42:240-241.
[22] Dai N, Yu YC, Ren TH, et al. Gynura root induces hepatic veno-occlusive disease: a case report and review of the literature. World J Gastroenterol, 2007, 13:1628-1631.
[23] Wang X, Qi X, Guo X. Tusanqi-Related Sinusoidal Obstruction Syndrome in China: a systematic review of the literatures. Medicine (Baltimore), 2015, 94:e942.
[24] Bearman SI, Anderson GL, Mori M, et al. Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol, 1993, 11:1729-1736. |
